Shots:

• The Korean MFDS has approved Celltrion’s IND to initiate a P-I trial of CT-P59 in patients with COVID-19. The company has initiated the enrollment and is set to evaluate the safety- tolerability- efficacy- PK- and immunogenicity of CT-P59 and anticipates the completion of study in Q3’20
• The company anticipates the results of P-II & P-III in patients with mild symptoms- the P-III trial in patients with mod. to sev. COVID-19- and the prevention clinical trial- by the end of 2020
• As part of the prevention study- Celltrion will enroll those who are in close contact with COVID-19 patients and those with no symptoms to evaluate the preventative effects of CT-P59

­ Ref: Celltrion | Image: Celltrion